Clinical Handbook of Psychotropic Drugs

Quick and comprehensive information on psychotropic drugs for adults.

Accurate and up-to-date Comparison charts help decision-making Icons and full color Available in print and online Downloadable patient info sheets

More about this book

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

Independent, unbiased, up-to-date Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug Potential interactions and side effects summarized in comparison charts With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek Clearly written patient information sheets available for download as printable PDF files

This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition

Neuroscience-based nomenclature – added to product availability tables Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso); also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)